iTeos Therapeutics (NASDAQ:ITOS) Earns “Outperform” Rating from Wedbush

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “outperform” rating reiterated by Wedbush in a research report issued to clients and investors on Thursday,RTT News reports. They currently have a $25.00 target price on the stock. Wedbush’s target price points to a potential upside of 214.47% from the company’s current price.

Separately, HC Wainwright reiterated a “buy” rating and issued a $46.00 price target on shares of iTeos Therapeutics in a research report on Friday, November 15th.

iTeos Therapeutics Price Performance

Shares of iTeos Therapeutics stock traded down $0.35 on Thursday, hitting $7.95. 467,970 shares of the company’s stock traded hands, compared to its average volume of 444,126. The firm’s 50-day moving average price is $8.82 and its two-hundred day moving average price is $13.08. The stock has a market capitalization of $290.45 million, a PE ratio of -2.52 and a beta of 1.37. iTeos Therapeutics has a one year low of $7.54 and a one year high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.13. On average, analysts forecast that iTeos Therapeutics will post -3.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Matthew Gall purchased 5,000 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were purchased at an average price of $7.73 per share, with a total value of $38,650.00. Following the completion of the purchase, the chief financial officer now owns 65,429 shares in the company, valued at $505,766.17. This represents a 8.27 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On iTeos Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Clearline Capital LP bought a new position in iTeos Therapeutics during the 2nd quarter worth about $2,328,000. Algert Global LLC boosted its position in shares of iTeos Therapeutics by 92.0% during the third quarter. Algert Global LLC now owns 256,139 shares of the company’s stock worth $2,615,000 after buying an additional 122,730 shares during the period. Candriam S.C.A. bought a new position in shares of iTeos Therapeutics during the second quarter worth about $7,558,000. Dimensional Fund Advisors LP raised its position in iTeos Therapeutics by 14.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock valued at $13,481,000 after buying an additional 117,159 shares during the last quarter. Finally, Readystate Asset Management LP lifted its stake in iTeos Therapeutics by 97.2% in the 3rd quarter. Readystate Asset Management LP now owns 169,819 shares of the company’s stock valued at $1,734,000 after acquiring an additional 83,700 shares in the last quarter. 97.16% of the stock is owned by institutional investors.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.